# A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

> **NCT07057271** · PHASE3 · COMPLETED · sponsor: **Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.** · enrollment: 464 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus - Poor Control

## Interventions

- **DRUG:** CJC-1134-PC Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07057271
- **Lead sponsor:** Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-02-21
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057271, "A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07057271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*